HLTH Community Insider, Zurich

In 2024, pharmaceutical companies expanded their external partnerships, collaborating with tech firms, academic institutions, and healthcare providers. These alliances aimed to accelerate drug discovery, enhance clinical trials, enrich HCP engagement and improve patient outcomes. While some partnerships led to breakthroughs in personalized medicine and data-driven research, others faced challenges in aligning goals and integrating different organizational cultures.

Looking to 2025, we may expect to see pharma collaborations intensifying, with a focus on AI-driven drug development, real-world evidence gathering, and innovative patient engagement strategies. What will the next wave of partnerships and collaborations look like and between what stakeholders? Does ''strategic'' imply no financial implications? Should incumbents be good partners beyond funding?

Join us to discuss how leveraging these partnership trends to stay ahead in the rapidly evolving pharmaceutical landscape can unlock new avenues for growth and innovation.